Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $1.31B |
| Gross Profit (TTM) | $322.09M |
| EBITDA | $125.57M |
| Operating Margin | 11.40% |
| Return on Equity | 16.20% |
| Return on Assets | 10.10% |
| Revenue/Share (TTM) | $15.87 |
| Book Value | $5.90 |
| Price-to-Book | 4.37 |
| Price-to-Sales (TTM) | 1.49 |
| EV/Revenue | 1.348 |
| EV/EBITDA | 14.99 |
| Quarterly Earnings Growth (YoY) | 78.90% |
| Quarterly Revenue Growth (YoY) | 5.30% |
| Shares Outstanding | $76.73M |
| Float | $70.15M |
| % Insiders | 1.98% |
| % Institutions | 110.73% |
Volatility is currently contracting
Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
Progyny (PGNY) remains the US market leader in fertility benefits management, demonstrating robust growth, improving margins, and a compelling valuation despite recent volatility. PGNY's Q2 2026 results highlight 11% revenue growth ex-Amazon, margin expansion, and nearly 100% EPS growth guidance for 2026, supporting a continued buy rating. Secular tailwinds—rising infertility rates, delayed family formation, and underpenetrated employer markets—position PGNY for sustained double-digit growth and market share gains.
The mean of analysts' price targets for Progyny (PGNY) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Tuesday, September 8, 2026, at 11:00 a.m. ET.
MNDY, MTCH, PGNY and WK make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.
IVZ, HUBS, HNGE and PGNY make the cut as the top liquid stocks, each boasting strong liquidity, growth attributes and operational efficiency.
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET.
Progyny NASDAQ: PGNY reported record quarterly revenue, gross profit and adjusted EBITDA for the second quarter of 2026, while management said early sales commitments and client-retention activity have positioned the company favorably for the 2027 selling season.
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended June 30, 2026 after the close of the market on Thursday, August 6, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PGNY and any ticker you trade — then tracks every position and per-strategy win rate.
